Remdesivir – CAS 1809249-37-3


Remdesivir (GS-5734) is synthesised by Santiago Lab (Prague, Czech Republic). It is one of the 5 compounds recommended by WHO for the investigation of the treatment of COVID-19. You can order remdesivir individually or as a set of 5 antivirotics recommended by WHO.

Purity (LC-MS)

99%, d.e. 95%+  |  Certificate of Analysis

Package contents


This compound is for research use only. We do not sell to patients.
10 mg

In stock

25 mg

In stock

50 mg

In stock

100 mg

In stock

1 g

In stock

2 g

In stock

5 g

In stock

SKU: N/A Category:


CAS: 1809249-37-3

IUPAC Name: 2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate

Other names: GS 5734; DB14761; SB19838, Remdesivir

Molecular weight: 602.58 g/mol

Molecular formula:C27H35N6O8P


Remdesivir (also known as GS-5734) is synthesised by Santiago Lab (Prague, Czech Republic). Remdesivir is an antiviral drug which belongs to the class of nucleotide analogues. It was mainly developed as a treatment for filovirus infections such as Ebola virus disease or Marburg virus. Subsequently, Remdesivir was found to show antiviral activity against other single-stranded RNA viruses such as respiratory syncytial virus, Nipah virus, Hendra virus, Junin virus, Lassa fever virus and the coronaviruses (including MERS and SARS viruses). Recently it is being studied as a promising medication for the treatment of COVID-19 (new SARS type virus).

Remdesivir, developed by Gilead Sciences, is an adenosine prodrug that metabolizes into its active form GS-441524 which interferes with the action of viral RNA-dependent RNA polymerase and evades proofreading by viral exoribonuclease (ExoN), causing a decrease in viral RNA production.

Chemicals are distributed worldwide

Buy Remdesivir now, get your order in 48 hours
  • Shipping through DHL in 48 hours
  • All compounds are safely and rigorously packed


  • We are sending the invoice the same day as the shipment
  • We are able to modify the invoice for the academic institution, so the order can be paid from grants

1. Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research 2020, 30 (3), 269-271.
2. Sheahan, T. P.; Sims, A. C.; Leist, S. R.; Schäfer, A.; Won, J.; Brown, A. J.; Montgomery, S. A.; Hogg, A.; Babusis, D.; Clarke, M. O., Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications 2020, 11 (1), 1-14.
3. Lai, C.-C.; Shih, T.-P.; Ko, W.-C.; Tang, H.-J.; Hsueh, P.-R., Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. International journal of antimicrobial agents 2020, 105924.
4. Ko, W.-C.; Rolain, J.-M.; Lee, N.-Y.; Chen, P.-L.; Huang, C.-T.; Lee, P.-I.; Hsueh, P.-R., Arguments in favour of remdesivir for treating SARS-CoV-2 infections. International journal of antimicrobial agents 2020.
5. Gordon, C. J.; Tchesnokov, E. P.; Feng, J. Y.; Porter, D. P.; Gotte, M., The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. Journal of Biological Chemistry 2020, jbc. AC120. 013056.
6. de Wit, E.; Feldmann, F.; Cronin, J.; Jordan, R.; Okumura, A.; Thomas, T.; Scott, D.; Cihlar, T.; Feldmann, H., Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences 2020, 117 (12), 6771-6776.
7. Tchesnokov, E. P.; Feng, J. Y.; Porter, D. P.; Götte, M., Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 2019, 11 (4), 326.
8. Pruijssers, A. J.; Denison, M. R., Nucleoside analogues for the treatment of coronavirus infections. Current opinion in virology 2019, 35, 57-62.
9. Hoenen, T.; Groseth, A.; Feldmann, H., Therapeutic strategies to target the Ebola virus life cycle. Nature Reviews Microbiology 2019, 17 (10), 593-606.
10. Brown, A. J.; Won, J. J.; Graham, R. L.; Dinnon III, K. H.; Sims, A. C.; Feng, J. Y.; Cihlar, T.; Denison, M. R.; Baric, R. S.; Sheahan, T. P., Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral research 2019, 169, 104541.
11. Agostini, M. L.; Andres, E. L.; Sims, A. C.; Graham, R. L.; Sheahan, T. P.; Lu, X.; Smith, E. C.; Case, J. B.; Feng, J. Y.; Jordan, R., Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 2018, 9 (2), e00221-18.
12. Siegel, D.; Hui, H. C.; Doerffler, E.; Clarke, M. O.; Chun, K.; Zhang, L.; Neville, S.; Carra, E.; Lew, W.; Ross, B.; Wang, Q.; Wolfe, L.; Jordan, R.; Soloveva, V.; Knox, J.; Perry, J.; Perron, M.; Stray, K. M.; Barauskas, O.; Feng, J. Y.; Xu, Y.; Lee, G.; Rheingold, A. L.; Ray, A. S.; Bannister, R.; Strickley, R.; Swaminathan, S.; Lee, W. A.; Bavari, S.; Cihlar, T.; Lo, M. K.; Warren, T. K.; Mackman, R. L., Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. Journal of Medicinal Chemistry 2017, 60 (5), 1648-1661.
13. Warren, T. K.; Jordan, R.; Lo, M. K.; Ray, A. S.; Mackman, R. L.; Soloveva, V.; Siegel, D.; Perron, M.; Bannister, R.; Hui, H. C.; Larson, N.; Strickley, R.; Wells, J.; Stuthman, K. S.; Van Tongeren, S. A.; Garza, N. L.; Donnelly, G.; Shurtleff, A. C.; Retterer, C. J.; Gharaibeh, D.; Zamani, R.; Kenny, T.; Eaton, B. P.; Grimes, E.; Welch, L. S.; Gomba, L.; Wilhelmsen, C. L.; Nichols, D. K.; Nuss, J. E.; Nagle, E. R.; Kugelman, J. R.; Palacios, G.; Doerffler, E.; Neville, S.; Carra, E.; Clarke, M. O.; Zhang, L.; Lew, W.; Ross, B.; Wang, Q.; Chun, K.; Wolfe, L.; Babusis, D.; Park, Y.; Stray, K. M.; Trancheva, I.; Feng, J. Y.; Barauskas, O.; Xu, Y.; Wong, P.; Braun, M. R.; Flint, M.; McMullan, L. K.; Chen, S.-S.; Fearns, R.; Swaminathan, S.; Mayers, D. L.; Spiropoulou, C. F.; Lee, W. A.; Nichol, S. T.; Cihlar, T.; Bavari, S., Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016, 531 (7594), 381-385.

Related products: